Cipher Pharmaceuticals (OTCMKTS:CPHRF – Get Free Report) (TSE:CPH) is anticipated to issue its resultson Thursday, November 5th. Analysts expect the company to post earnings of $0.1989 per share and revenue of $12.23 million for the quarter.
Cipher Pharmaceuticals Stock Performance
Shares of CPHRF opened at $9.61 on Thursday. The business’s fifty day moving average price is $9.97 and its 200 day moving average price is $11.41. Cipher Pharmaceuticals has a 12-month low of $8.92 and a 12-month high of $15.00.
About Cipher Pharmaceuticals
Cipher Pharmaceuticals Inc is a specialty pharmaceutical company focused on developing, acquiring and commercializing prescription medicines, primarily in dermatology. The company has built its business around products that address conditions such as severe acne, actinic keratosis and other skin disorders.
Cipher’s portfolio has included Epuris, an oral isotretinoin product used to treat severe acne, and Actikerall, a topical treatment for actinic keratosis. The company has also been associated with dermatology products such as Vaniqa, a prescription cream for unwanted facial hair, and Pliaglis, a topical anesthetic product.
Read More
- Five stocks we like better than Cipher Pharmaceuticals
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
Receive News & Ratings for Cipher Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
